I N V E S T O R W E B I N A R · 1 9 N O V E M B E R 2 0 2 6 T R I A L S N A P S H O T M I L E S T O N E A C H E I V E D Sheba Medical Center ethics approval EMILI (18 November 2026) P R I N C I P A L I N V E S T I G A T O R Evaluation of a MYC - silencing Intervention in Acute Myeloid LeukemIa...
EMILI Investor Webinar Nov 2026
Filed with ASX · · 18 pages · English and French
Summary by 6ix AI
Racura Oncology Ltd has announced an investor webinar regarding the EMILI trial, which focuses on a MYC-silencing intervention for acute myeloid leukemia. The trial has received ethics approval from Sheba Medical Center, allowing it to move forward toward patient enrollment expected in the first quarter of the following year. The company plans to expand the trial globally, with additional sites anticipated to open in various regions, contingent on regulatory approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Racura Oncology
- Sheba Grants Ethics Approval for EMILI AML Trial
- Racura Successfully PK Bridges RC110 RC220
- Racura Presents Bisantrene MYC Data at FCS 2026
- Letter to Shareholders, Notice of AGM & Proxy Form
- Sept 2026 Quarterly Activities Report and Appendix 4C
